Close Menu
Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

PRSA‑NY Opens Submissions for 2026 Big Apple Awards, Honoring Communications Excellence Across the New York Metro Area

March 24, 2026

Thomas Global Systems’ Abrams Immersive Tactical Trainer (ITT) showcased to US Government and industry partners

March 24, 2026

Prairie Harm Reduction fires executive director, citing ‘significant’ deficit

March 24, 2026

Canada discusses Keystone XL revival with Trump administration officials

March 24, 2026

Corus recapitalization plan approved by Ontario court

March 24, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » Schizophrenia Drugs Market Forecasted at $9.46 Billion by 2030, Driven by the Rising Focus on Injectable Treatments and Second-Generation Therapeutics
Press Release

Schizophrenia Drugs Market Forecasted at $9.46 Billion by 2030, Driven by the Rising Focus on Injectable Treatments and Second-Generation Therapeutics

By News RoomJanuary 31, 20243 Mins Read
Schizophrenia Drugs Market Forecasted at .46 Billion by 2030, Driven by the Rising Focus on Injectable Treatments and Second-Generation Therapeutics
Share
Facebook Twitter LinkedIn Pinterest Email

Dublin, Jan. 31, 2024 (GLOBE NEWSWIRE) — The “Schizophrenia Drugs Market, Size, Global Forecast Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis” report has been added to ResearchAndMarkets.com’s offering.

This comprehensive research on the global Schizophrenia Drugs Market indicates a projected expansion to a size of US$ 9.46 billion by 2030, marking a CAGR of 3.51% from 2023 to 2030.

The analysis sheds light on the complexities of schizophrenia, a mental health disorder with significant health implications and challenges for patients and healthcare systems worldwide. With an emphasis on the introduction of second- and third-generation antipsychotic drugs, the market is witnessing a paradigm shift in treatment preferences. These newer antipsychotics are favored for their reduced side effects compared to first-generation medications. The landscape is further catalyzed by a consistent rise in FDA approvals catering to these advanced treatment options.

Retail Pharmacies Gain Greater Market Share with Improved Accessibility to Antipsychotic Drugs

The study segments the market by treatment method, revealing a vigorous growth trajectory for injectable schizophrenia drugs. This segment’s prominence can be traced to their long-term effectiveness in relapse prevention and improved adherence due to lower dosing frequencies.

Secondary Therapeutic Class Witnesses Surge in Demand

As the report delineates, the second-generation antipsychotics segment is set to experience significant growth. With an ever-increasing burden of mental health disorders worldwide, these medications offer hope with their proven efficacy in managing symptoms, such as hallucinations and delusions, commonly associated with schizophrenia.

Asia Pacific and Notably China Show Robust Growth within the Schizophrenia Drugs Market

Specifically spotlighting regional developments, China is identified as showing remarkable growth within the Asia Pacific schizophrenia drugs market. Factors such as a growing geriatric population, which is more prone to late-onset schizophrenia, and heightened health infrastructure investments underpin this surge. The extensive report provides invaluable insights into the market dynamics, segmented by class, treatment, end-user distribution channels, and a detailed country-wise analysis. The research reflects the considerable efforts of key players identified within the sector, including their strategies and financial snapshots.

End-user Preference Trends: Hospital vs. Retail vs. Online Pharmacies

Distribution channels play an integral role in the Schizophrenia Drugs Market, with retail pharmacies securing a dominant share. The convenience and accessibility they offer affirm their essential position in the distribution network for schizophrenia drugs. The study anticipates this trend to continue, highlighting the role of retail pharmacies in the broader mental health ecosystem.

Comprehensive Global and Regional Market Analysis

The document meticulously analyzes 18 countries, providing a nuanced perspective on the global and regional markets. It includes the markets of the Americas, Europe, Asia Pacific, the Middle East, Africa, and the Rest of the World, detailing each region’s contributions to the overall market landscape.

Key Attributes

Report Attribute Details
No. of Pages 165
Forecast Period 2023-2030
Estimated Market Value (USD) in 2023 $7.43 Billion
Forecasted Market Value (USD) by 2030 $9.46 Billion
Compound Annual Growth Rate 3.5%
Regions Covered Global

Companies Mentioned

  • H Lundbeck
  • Pfizer Inc.
  • AbbVie
  • AstraZeneca
  • Bristol Myers Squibb
  • Eli Lilly
  • GlaxoSmithKline
  • Johnson & Johnson
  • Takeda Pharmaceuticals
  • Novartis AG

For more information about this report visit https://www.researchandmarkets.com/r/gl77jt

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

  • Global Schizophrenia Drugs Market

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

PRSA‑NY Opens Submissions for 2026 Big Apple Awards, Honoring Communications Excellence Across the New York Metro Area

Thomas Global Systems’ Abrams Immersive Tactical Trainer (ITT) showcased to US Government and industry partners

Dycom Industries, Inc. Appoints Raejeanne Skillern to Board of Directors

Erdene Announces 2025 Results – Provides Bayan Khundii Gold Mine and Exploration Update

Epirus, General Dynamics Land Systems and Kodiak AI Unveil New Autonomous HPM System for Counter-UAS

American Airlines elects Mary Dillon to its board of directors

PROLIM Expands Global Salesforce, Snowflake, and Industrial AI Capabilities by Rebranding Kasmo Digital

Nasdaq Announces Mid-Month Open Short Interest Positions in Nasdaq Stocks as of Settlement Date March 13, 2026

WellSpan Health opens new hospital in southern York County, the second of three opening in Central Pennsylvania

Editors Picks

Thomas Global Systems’ Abrams Immersive Tactical Trainer (ITT) showcased to US Government and industry partners

March 24, 2026

Prairie Harm Reduction fires executive director, citing ‘significant’ deficit

March 24, 2026

Canada discusses Keystone XL revival with Trump administration officials

March 24, 2026

Corus recapitalization plan approved by Ontario court

March 24, 2026

Latest News

Dycom Industries, Inc. Appoints Raejeanne Skillern to Board of Directors

March 24, 2026

Erdene Announces 2025 Results – Provides Bayan Khundii Gold Mine and Exploration Update

March 24, 2026

Epirus, General Dynamics Land Systems and Kodiak AI Unveil New Autonomous HPM System for Counter-UAS

March 24, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version